Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively. A recent study by researchers at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences reveals global and drug-specific cellular effectors needed for TPD. The results have now been published in the scientific journal Molecular Cell.
- Molecular Cell
- Austrian Academy of Sciences, EMBO long-term fellowship, Boehringer Ingelheim Fonds (BIF) PhD fellowship